Drugmaker Novartis AG said it will procure MorphoSys AG, an engineer of malignant growth therapies, for 2.7 billion euros ($2.9 billion), adding a promising interesting bone-marrow disease treatment possibility to its portfolio. Novartis will...
MedGenome, a leading global technology company in South Asia, and the Parkinson's Research Alliance of India (PRAI) conducted a study that identified rare and common variants based on the Polygenic Risk Score (PRS) in Young Onset.
Acepodia's, a clinical biotechnology company, is developing best-in-class therapeutics with its unique antibody-cell conjugate (ACC) and allergenic gamma delta 2(d2) T cells to address cancer treatment areas, one of the US. The food.
Merck Animal Health, known outside the United States and Canada as MSD Animal Health, a division of Merck and Co., Inc.,
India has great potential for international relations in pharmaceutical education, says Dr. Ilkay Erdogan Orhan, Dean of the Faculty of Pharmacy at Gazi University, Ankara, Turkey.
A Russian company approached the Indian embassy in Moscow in search of 27 high-quality vaccines similar to those produced by Western medical authorities.
Sirius Therapeutics, a creative, clinical stage biotech organization, declared it has dosed the main subject in a stage 1, first-in-human clinical preliminary in Australia of SRSD107 on January 30, 2024, its cutting edge siRNA restorative...
Regeneron Pharmaceuticals, Inc. published a marketing authorization application (MAA) to the European Medicines Agency (EMA) for the treatment of elderly patients with relapsed/refractory (R/R) multiple myeloma (MM).
The UK is now participating in an international clinical trial where cancer patients will receive a new treatment to help them identify and fight cancer cells. The first recipients of this experimental mRNA therapy.
To ensure a smooth transition for accredited laboratories, the National Accreditation Board for Laboratories (NABL) has announced that it will extend the transition period for certified laboratories from the original deadline of 31 December
, CDSCO.jpg)
